EVALUATION OF TREATMENT OUTCOMES WITH TDF OVER A 5-YEAR PERIOD IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (2020 -2025)
Main Article Content
Abstract
Objective: To evaluate the long-term effectiveness of TDF (300 mg/day) in the treatment of chronic hepatitis B, we conducted a retrospective study of 180 patients receiving treatment at the Outpatient Clinic of Hospital A – Thai Nguyen, from 2020 to 2025.
Results: Over a 5-year period, clinical manifestations-including the presence of ascites—gradually stabilized; however, in 3 patients who had cirrhosis prior to treatment, hepatosplenomegaly persisted. After 3 years of treatment, 100% of HBV-DNA viral loads were below the threshold (average 3.62 ± 1.53 months), and coagulation parameters, albumin, and bilirubin were all stable. Liver fibrosis/cirrhosis and HBeAg seroconversion were improving. No viral outbreaks or complications (on ultrasound and AFP) were observed. However, anemia and thrombocytopenia did not improve, the percentage of patients with ALT enzyme levels above the threshold ranged from 23.1% to 40.3%, there were 2 cases of mild renal failure (1 case before treatment) and 2 cases of osteoporosis.
Conclusion: TDF is effective in inhibiting the virus, improving blood clotting and metabolic functions in the liver, and restoring the condition of liver fibrosis. It is necessary to monitor for anemia, renal function, osteoporosis, and the long-term efficacy of TDF.
Keywords
Chronic hepatitis B, liver fibrosis, HBV-DNA load, TDF
Article Details
References
2. Bộ Y Tế. Quyết định 7034/QĐ-BYT về việc ban hành tài liệu Hướng dẫn Quy trình kỹ thuật chuyên ngành Hóa sinh, ngày 21 tháng 11 năm 2018 của Bộ trưởng Bộ Y Tế.
3. Vương Trường Cửu, Nguyễn Thị Thu Huyền, Lê Quốc Tuấn. Kết quả điều trị bệnh nhân viêm gan virus B mạn tính bằng Tenofovir Disoproxil Fumarate (TDF) tại bệnh viện Đa khoa tỉnh Phú Thọ; Y học Việt Nam. 2024;538(2):101-104.
4. Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457-1464. doi:10.1007/s10620-014-3486-7
5. Liang X, Gao Z, Xie Q, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13(3):260-269. doi:10.1007/s12072-019-09943-6
6. Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol WJG. 2015;21(18):5524-5531. doi:10.3748/wjg.v21.i18.5524
7. Rao H, Shang J, Xie Q, et al. Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis. ILIVER. 2022;1(3):145-153. doi:10.1016/j.iliver.2022.08.006
8. World Health Organization. Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. World Health Organization; 2024. Accessed September 24, 2026. http://www.ncbi.nlm.nih.gov/books/NBK614989/